But questions about gene therapy safety could benefit the enzyme-replacement therapy incumbents.
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.